methyl 4-[2-(pyrimidin-2-ylamino)ethyloxy]benzoate | 174665-27-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 4-[2-(pyrimidin-2-ylamino)ethyloxy]benzoate
• 英文别名: Methyl 4-[2-(pyrimidin-2-ylamino)ethoxy]benzoate
• CAS: 174665-27-1
• 化学式: C₁₄H₁₅N₃O₃
• 分子量: 273.291
• InChiKey: LZWAIRWMNUGLFS-UHFFFAOYSA-N

物化性质

• 沸点：
  466.9±51.0 °C(Predicted)
• 密度：
  1.252±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  20
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  73.3
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  methyl 4-[2-(pyrimidin-2-ylamino)ethyloxy]benzoate 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 2.0h， 以65%的产率得到4-[2-(2-嘧啶氨基)乙氧基]苯甲酸
  参考文献：
  名称：

  Nonpeptide α_vβ₃ Antagonists. 1. Transformation of a Potent, Integrin-Selective α_IIbβ₃ Antagonist into a Potent α_vβ₃ Antagonist

  摘要：

  Modification of the potent fibrinogen receptor (alpha(IIb)beta(3)) antagonist 1 generated compounds with high affinity for the vitronectin receptor alpha(v)beta(3). Sequential modification of the basic N-terminus of 1 led to the identification of the 5,6,7,8-tetrahydro[1,8]naphthyridine moiety (THN) as a lipophilic, moderately basic N-terminus that provides molecules with excellent potency and selectivity for the integrin receptor alpha(v)beta(3). The THN-containing analogue 5 is a potent inhibitor of bone resorption in vitro and in vivo. In addition, the identification of a novel, nonpeptide radioligand with high affinity to alpha(v)beta(3) is also reported.

  DOI：

  10.1021/jm000133v
• 作为产物：
  描述：

  N-[2-(4-Methoxycarbonylphenoxy)ethyl]phthalimide 在 N,N-二异丙基乙胺 、 肼 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 36.0h， 生成 methyl 4-[2-(pyrimidin-2-ylamino)ethyloxy]benzoate
  参考文献：
  名称：

  Nonpeptide α_vβ₃ Antagonists. 1. Transformation of a Potent, Integrin-Selective α_IIbβ₃ Antagonist into a Potent α_vβ₃ Antagonist

  摘要：

  Modification of the potent fibrinogen receptor (alpha(IIb)beta(3)) antagonist 1 generated compounds with high affinity for the vitronectin receptor alpha(v)beta(3). Sequential modification of the basic N-terminus of 1 led to the identification of the 5,6,7,8-tetrahydro[1,8]naphthyridine moiety (THN) as a lipophilic, moderately basic N-terminus that provides molecules with excellent potency and selectivity for the integrin receptor alpha(v)beta(3). The THN-containing analogue 5 is a potent inhibitor of bone resorption in vitro and in vivo. In addition, the identification of a novel, nonpeptide radioligand with high affinity to alpha(v)beta(3) is also reported.

  DOI：

  10.1021/jm000133v

文献信息

• US5741796A
  申请人：——

  公开号：US5741796A

  公开（公告）日：1998-04-21
• US5929120A
  申请人：——

  公开号：US5929120A

  公开（公告）日：1999-07-27
• Nonpeptide α_vβ₃ Antagonists. 1. Transformation of a Potent, Integrin-Selective α_IIbβ₃ Antagonist into a Potent α_vβ₃ Antagonist
  作者：Mark E. Duggan、Le T. Duong、John E. Fisher、Terence G. Hamill、William F. Hoffman、Joel R. Huff、Nathan C. Ihle、Chih-Tai Leu、Rose M. Nagy、James J. Perkins、Sevgi B. Rodan、Gregg Wesolowski、David B. Whitman、Amy E. Zartman、Gideon A. Rodan、George D. Hartman

  DOI：10.1021/jm000133v

  日期：2000.10.1

  Modification of the potent fibrinogen receptor (alpha(IIb)beta(3)) antagonist 1 generated compounds with high affinity for the vitronectin receptor alpha(v)beta(3). Sequential modification of the basic N-terminus of 1 led to the identification of the 5,6,7,8-tetrahydro[1,8]naphthyridine moiety (THN) as a lipophilic, moderately basic N-terminus that provides molecules with excellent potency and selectivity for the integrin receptor alpha(v)beta(3). The THN-containing analogue 5 is a potent inhibitor of bone resorption in vitro and in vivo. In addition, the identification of a novel, nonpeptide radioligand with high affinity to alpha(v)beta(3) is also reported.